IAP7 Pec'd PCT/PTO 15 FEB 2006

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

February 15, 2006

Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNIEV'S DOCKET NUMBER													
	10-96		Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 4-33361A									
		TRANSMITTAL LETTER TO T	U.S. APPLICATION NO. (If-known, see 37 CFR 1.5)										
		DESIGNATED/ELECTED O	10/568486										
		CONCERNING A FILING UN		667 300400									
INT	ER	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED									
		4/010260	14 September 2004 (14.09.04)	15 September 2003 (15.09.03)									
	TITLE OF INVENTION ()												
1,3 DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE													
TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES													
APPLICANT(S) FOR DO/EO/US DARREN MARK LEGRAND													
DARKEN WARK ELOKAND													
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:													
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.											
2.		This is a SECOND or SUBSEQUENT sul	bmission of items concerning a filing und	der 35 U.S.C. 371.									
3.) at any time rather than delay												
4.	\square	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority											
		date.											
5.	\boxtimes	A copy of the International Application as		-1 D									
		a. is transmitted herewith (required of b. A has been transmitted by the Inter-	only if not transmitted by the international national Bureau. (See Form PCT/IB/30										
		c. is not required, as the application	g Office (RO/US).										
6.		A translation of the International Application into English (35 U.S.C. 371(c)(2)).											
7.	\boxtimes	Amendments to the claims of the Internat	ional Application under PCT Article 19 (35 U.S.C.371(c)(3)).									
		b. have been transmitted by the Inte	d only if not transmitted by the Internatio	nai Bureau).									
		c. have not been made; however, the	ne time limit for making such amendmen	ts has NOT expired.									
_	_	d. A have not been made and will not	be made.	·									
8. 9.	H	A translation of the amendments to the cl	71 (c)(3)). (c)(4))										
	 An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 												
	371(c)(5)).												
Iten	ns 1	1. to 16. below concern document(s) or	information included.	_									
11.		An Information Disclosure Statement und	er 37 CFR 1.97 and 1.98.										
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.											
13.	\boxtimes	A FIRST preliminary amendment.											
		A SECOND or SUBSEQUENT preliminar	y amendment.										
14.	\boxtimes	An Application Data Sheet under 37 CFR 1.76.											
15.		A substitute specification.											
16.		A change of power of attorney and/or add	iress letter.										
17.		A computer-readable form of the sequence	ce listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821-1.825.									
18.		A second copy of the published Internation	nal Application under 35 U.S.C. 154(d)(4).									
19.		A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).											

20. igstyle Other items or information: unexecuted Declaration

LAP20 Rec'd PCTAPTO 15 FEB 2006

U.S. APPLICATION NO	o) (if known		මීරා E	ITERNATIONAL APPLICATION P2004/010260	NO.		4-33361A	DOCKET NUMBER				
The following fe	Marine Makes States and	TELEVISION OF THE		and the state of t	kgg (trait the vice) ne a	tenderate de l'appendir sol tras acculos	ewerphy and the second second	THE RESERVE OF THE PARTY OF THE	IONS PTO USE			
N N							•		······································			
	21.											
22. Examination Fee If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)												
⊠ Allo	\$200											
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international												
application to the USPTO as an International Searching Authority \$ ☑ If International Search Report was prepared and provided to the Office \$400 ☐ All other situations												
		\$ 90	0									
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.												
Total Sheets	Extra	sheets		each additional 50 o und up to a whole nu			RATE					
81 - 100 =	0	/50 =		0		X	\$ 250	\$				
Surcharge of \$1 months from the		\$										
CLAIMS Total claims		10	ER FILED	NUMBER EXT	RA	_ _ x	RATE 50	\$				
Independent cla	ims	1	- 3	=		X \$	200	\$				
MULTIPLE DEF	PENDEN	T CLAIM(S) (if applicab			+ \$	360	\$				
Peduction of 1/2	for filing	a by small o	ntity if appli	TOTAL OF A cable. Verified Small				\$ 90	0			
filed (Note 37 C	FR 1.9,	1.27, 1.28).	пису, п аррп		- Entity S			\$				
Processing fee	of \$130 f	or furnishin	a the English	h translation later tha	n 🗆 3	SI 0 months f	UBTOTAL =	\$ 90	0			
earliest claimed				Translation later tha			+	\$				
		 					NAL FEE =	\$ 90	0			
by an appropria	g the en te cover	closed assig sheet (37 C	gnment (37 (FR 3.28, 3.3	CFR 1.21(h)). The as 31). \$40 per property	ssignme: /	nt must be	accompanied +	\$:			
		•				EES EN	NCLOSED =	\$ 90	0			
								Amount t				
								be: refunde charge				
a. A chec	k in the a	amount of \$		to cover the ab	ove fees	is enclos	ed.	Land Control of the C	Confidence Leville (Confidence Confidence Co			
			ount No. 19 is enclosed.	-0134 in the name of	Novartis	in the am	nount of \$900 to	cover the abo	ve fees. A			
c. 🛛 The Co Deposi	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Gregory C. Hbughton Attorney for Applicant Reg. No. 47,666 (862) 778-2614												
Date: 2	Date: 2/15/06											